This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 (NCT04605588), a randomized phase 2 study. The primary outcome is Rate of Decline in Viral Load Over the 10 Days After Randomization.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04605588 |
| Phase | Phase 2 |
| Condition | SARS-CoV Infection, Covid19 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 7 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Results posted | Yes |
2. Clinical Question
Population
Participants with proven SARS-CoV-2 infection, enrolled within 7 days after diagnosis. The study was intended for outpatient treatment.
Intervention
Five-day dosing with nitazoxanide, ribavirin and hydroxychloroquine sulfate.
Comparator
Five-day dosing with placebo.
Primary question
Does the combination change the rate of decline in viral load over the 10 days after randomization, measured by nasal-swab qPCR?
The clinical question was whether the three-drug combination would be associated with a different rate of viral-load decline than placebo. The registry also describes an interest in illness severity after treatment and active follow-up for 28 days, but it identifies the rate of decline in viral load as the primary outcome.
This question was framed for participants with confirmed infection who could enter soon after diagnosis. The registry describes an intended enrollment of 70 participants, while the study was terminated because of lack of enrollment and reports that 7 participants were randomized. The registry does not report a treatment-effect estimate or an analysis of the primary outcome. Thus, the clinical question is clear, but the posted record does not provide an answer about the comparative viral-load trajectories.
3. Trial Design
TriACT was a phase 2 randomized trial with a parallel-group design. The registry describes quadruple masking, meaning that masking was intended across multiple trial roles; it does not specify in the record which roles those were. The active group was assigned five-day dosing with nitazoxanide, ribavirin and hydroxychloroquine sulfate, and the placebo group was assigned five-day dosing with placebo.
The study began on 2020-12-02, had a primary completion date of 2021-01-17, and is listed as terminated. The registry states that termination was due to lack of enrollment. It reports an intended enrollment of 70 in the study summary and an enrollment of 7, with 7 participants randomized, in the trial record. The reason for the difference between intended and recorded enrollment is described as lack of enrollment; further operational details are not reported in the registry record.
The planned primary assessment concerned viral-load decline over the 10 days after randomization, measured using qPCR from nasal swabs. Participants were to be actively followed for 28 days. The registry does not report the details of the randomization sequence, allocation concealment, visit schedule, or procedures for maintaining masking. It also does not report a statistical analysis plan or explain whether the trial design was changed before termination. The available record therefore establishes the broad design and intended comparison, but not the full conduct or analysis procedures.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Active Study Drug | Placebo |
|---|---|---|
| STARTED | 2 | 5 |
| COMPLETED | 1 | 5 |
| NOT COMPLETED | 1 | 0 |
Reasons for not completing this period:
| Reason | Active Study Drug | Placebo |
|---|---|---|
| Withdrawal by Subject | 1 | 0 |
Analysis population for the primary outcome, as defined in the registry: This trial was terminated due to lack of enrollment. A total of 7 participants were randomized. Study outcome was to be response to antiviral treatment (rate of decline in viral load over the 10 days after randomization) as measured via nasal swab qPCR analysis. Based on the lack of enrollment, the swab analysis was not performed.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Active Study Drug | Placebo | Total |
|---|---|---|---|---|
| Participants analysed | 2 | 5 | 7 | |
| Age, Continuous | years | 38 (SD 2.8) | 44 (SD 15.0) | 42 (SD 12.6) |
| Sex: Female, Male: Female | Participants | 2 | 3 | 5 |
| Sex: Female, Male: Male | Participants | 0 | 2 | 2 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 1 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 2 | 4 | 6 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Rate of Decline in Viral Load Over the 10 Days After Randomization, measured over 10 days after randomization.
| Element | Registry entry |
|---|---|
| Result type | N/A |
| Measure of spread | not applicable |
| Unit | not stated |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint was the rate of decline in viral load over the 10 days after randomization, measured by qPCR from nasal swabs. qPCR is a laboratory method used to quantify viral genetic material. A rate-based endpoint is intended to describe how measurements change over time rather than to compare only a single measurement. In general, such an endpoint can capture the trajectory of a biological measure across the stated observation period.
For this trial, comparing rates between the active-treatment and placebo groups would have addressed whether their viral-load trajectories differed during the primary assessment period. The registry record does not specify the units, exact calculation of the rate, model, handling of measurements below assay limits, or the summary measure to be used in the comparison. Those details are important for interpreting a rate estimate and are not reported in the registry record.
The registry states that the trial was terminated due to lack of enrollment and reports 7 randomized participants, but it does not report the primary-outcome results. No rate estimate, group-level viral-load trajectory, confidence interval, or statistical test for this endpoint is reported in the registry record. Consequently, the endpoint describes what the trial set out to measure, not an observed treatment effect established by the posted results.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The record establishes the intended comparison: five-day dosing with nitazoxanide, ribavirin and hydroxychloroquine sulfate versus five-day placebo, with viral-load decline over the 10 days after randomization as the primary outcome. It also establishes that the trial was randomized, parallel-group, quadruple-masked, and terminated due to lack of enrollment. Seven participants were randomized; the registry had described an intended enrollment of 70.
These registry entries do not provide a comparative efficacy estimate. The registry does not report the viral-load measurements, the rate of decline in either group, an estimated between-group contrast, a confidence interval, or a p-value. It reports no analyses. Without those results, the direction and size of any difference between groups cannot be assessed, and the precision of an effect estimate cannot be described.
In general, a confidence interval communicates the range of effect values compatible with the data under a specified statistical method. A narrow interval indicates greater precision than a wide interval, although interpretation also depends on the endpoint and analysis. No interval for the primary outcome is reported in the registry record, so the precision of a treatment comparison cannot be evaluated. A p-value, if reported, would address compatibility with a specified null hypothesis under a model; it would not by itself describe the size or clinical importance of an effect. No primary-outcome p-value is reported.
The registry describes the study as terminated because of lack of enrollment. That limits the record's ability to support a treatment-effect assessment, but the reason for termination does not itself establish what the treatment comparison would have shown. The intended enrollment and actual randomized enrollment should not be confused with an analyzed sample or with a powered result. The analysis populations and endpoint-specific numbers of observations are not reported in the registry record.
Safety fields report zero serious adverse events and zero deaths in each listed group. Those figures are counts in the posted safety record; they do not substitute for the missing primary-outcome comparison. The listed safety denominators also do not account for all participants reported as randomized, and the reason is not reported in the registry record. Taken together, the posted information documents the trial's design, termination, and limited safety counts, but does not allow a statistical conclusion about comparative viral-load change.
9. Statistical Methods Explained
The methods that can be described from the registry record are the randomized, parallel-group design, the quadruple-masking designation, the active and placebo regimens, and the primary endpoint. The record does not report the detailed statistical analysis plan. The explanations below distinguish general statistical principles from methods documented for TriACT.
What does randomization contribute?
In general, randomization assigns participants to treatment groups using a chance-based process. It is intended to reduce systematic differences between groups at the start of a trial, including differences that investigators may not have measured. It does not guarantee that groups will be identical, and it does not remove uncertainty, especially when the amount of information available is limited. The record identifies TriACT as randomized but does not describe sequence generation or allocation concealment. Those details are not reported in the registry record.
What does a parallel-group design mean?
In general, a parallel-group trial assigns participants to a study group and compares outcomes between groups. The TriACT record describes an active study-drug group and a placebo group. It does not describe crossover between regimens. A comparison in this design depends on the outcome definition, the analysis population, the handling of follow-up measurements, and the statistical model. The model planned for the primary endpoint is not reported in the registry record.
How should masking be understood?
In general, masking is intended to reduce the influence of treatment knowledge on trial conduct, outcome assessment, or reporting. The registry labels TriACT quadruple-masked but does not identify which participants, clinical staff, investigators, or analysts were masked. It also does not report how masking was maintained or assessed. The designation therefore describes the recorded design label, not the details of implementation.
What does the rate endpoint require?
In general, estimating a rate of change requires repeated measurements or another defined way of representing change over time. The trial's stated measure was viral load assessed by nasal-swab qPCR, with the rate evaluated over the 10 days after randomization. A statistical analysis could summarize change using a specified model, but the choice of model affects the estimate and its uncertainty. The registry record does not report the measurement schedule, rate formula, model, or assumptions. It is therefore not possible to reconstruct the intended analysis from the posted description.
Why do uncertainty and dispersion matter?
In general, an effect estimate is more informative when accompanied by an uncertainty measure such as a confidence interval. The interval reflects both the observed data and the assumptions of the analysis. Dispersion describes how variable observations are around a summary or model; greater variability generally makes an estimate less precise when other aspects of the study are held constant. For repeated viral-load measurements, within-participant variation and differences between participants can both matter. The record reports no dispersion estimate or confidence interval for the primary outcome, and no model details from which these quantities could be understood.
What can planning calculations say?
In general, sample-size calculations are conditional planning exercises: they depend on assumptions about an effect, variability, allocation, significance level, and analysis. They are not results from participants and do not establish the power achieved by a completed trial. The stated planning framework uses a two-sided significance level of 0.05, equal allocation between the groups, a normal approximation, and effects defined as stated fractions of an observed effect. The registry record does not report a trial-specific statistical plan or a justification for the intended enrollment. Any sample-size illustrations should therefore be read as planning calculations under assumptions, not as observed power or evidence of a treatment effect.
The record reports no primary-outcome analyses. As a result, there is no sponsor analysis to compare with a recalculation, and no basis to assess whether an adjusted or unadjusted analysis was used. The analysis method, treatment of repeated observations, missing-data method, and any covariate adjustment are not reported in the registry record.
10. Multiplicity, Missing Data and Analysis Populations
Multiplicity arises when a study evaluates several outcomes, time points, groups, or statistical comparisons. In general, making many inferences can increase the chance of obtaining a nominally notable result by chance unless the analysis plan addresses that issue. The registry lists one primary outcome measure, but the primary-outcome description refers to a rate over the 10 days after randomization. The record does not report whether there were additional planned comparisons, how repeated measurements were to be analyzed, or whether any multiplicity adjustment was planned. A multiplicity strategy is not reported in the registry record.
The registry reports no analyses. It does not provide a missing-data method, the number of observed primary-endpoint measurements, or an account of participants who did not contribute endpoint data. The analysis populations, such as the population intended for the primary comparison, are not reported in the registry record. It is therefore not possible to determine from the posted information how participants were included in an analysis or how incomplete follow-up would have been handled.
In general, missing data can affect an estimate when the availability of measurements is related to participants' outcomes or characteristics. Methods for handling missingness rely on assumptions, and those assumptions should be made clear when results are reported. The record gives no method or sensitivity analysis for missing data. It also does not explain the discrepancy between the randomized enrollment and the at-risk counts listed in the safety information. These omissions limit assessment of both the planned inference and the completeness of the posted results.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Active Study Drug | 0 | 1 | 0.0% |
| Placebo | 0 | 5 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Active Study Drug | 0 of 1 |
| Placebo | 0 of 5 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Active Study Drug | 0 of 1 |
| Placebo | 0 of 5 |
The posted safety fields list the active study-drug group with 1 participant at risk for serious adverse events and 0 affected, and the placebo group with 5 participants at risk and 0 affected. The same at-risk and affected counts are listed for other adverse events. Deaths are listed as 0 in each group, and no serious adverse-event terms are listed.
These are counts in the registry safety record, not estimates of comparative risk. In general, an at-risk denominator indicates the number included in a particular safety summary; it need not be the same as the randomized enrollment or the denominator used for another outcome. Here, the listed at-risk counts do not account for all 7 participants reported as randomized. The reason for this is not reported in the registry record.
Zero recorded events means that the posted fields list no events in those categories for the stated denominators. It does not establish that an event could not occur, and it does not resolve the missing information about who contributed safety data. The small and incomplete safety accounting should therefore be read narrowly as the event counts recorded, not as a precise comparison of safety between regimens.
12. What the Result Does, and Does Not, Mean
The registry record documents a randomized phase 2 trial comparing a three-drug regimen with placebo and identifies viral-load decline over the 10 days after randomization as the primary outcome. It also reports that the trial was terminated because of lack of enrollment, with 7 participants randomized against an intended enrollment of 70. These details explain why the posted record is limited, but they do not show whether viral-load outcomes differed between groups.
The primary-outcome result, effect estimate, uncertainty interval, and statistical test are not reported in the registry record. Consequently, the posted results cannot establish the size or direction of a treatment difference, nor how precisely such a difference was estimated. The absence of an analysis is not evidence that the treatments had equal outcomes. It is also not evidence that the combination changed viral load. Neither conclusion follows from the information reported.
In general, a trial's design states the question and planned comparison, while its results require observed outcome data and an analysis. Enrollment information alone cannot answer an outcome question. Likewise, counts of serious adverse events and deaths cannot replace the primary endpoint analysis. The safety record reports zero events in the listed categories and groups, but its at-risk counts do not account for all randomized participants, and the reason is not reported in the registry record.
Any sample-size calculations associated with this trial are planning illustrations under stated assumptions, not a measure of power achieved or a substitute for outcome results. The registry's stated planning assumptions do not supply the missing viral-load analysis. The appropriate interpretation is therefore limited: the trial was designed to compare the regimens on a specified viral-load measure, but the posted record does not report the comparison needed to assess that question.
13. Why This Trial Matters Statistically
This trial illustrates the difference between a clearly stated research question and an answer supported by outcome data. The registry identifies the intervention, placebo comparator, primary viral-load endpoint, assessment period, and broad trial design. It also records termination due to lack of enrollment and reports 7 randomized participants. Yet it provides no primary-outcome analysis. Without that analysis, readers cannot estimate the treatment contrast or assess its precision.
Statistically, the distinction matters because design labels and enrollment counts do not determine what the observed outcome would have been. Randomization is a design feature; an effect estimate and its uncertainty require analyzed data. In general, the estimate and confidence interval together describe both the direction and precision of a comparison. Neither is reported for the primary endpoint in the registry record.
The record also highlights the importance of transparent reporting about analysis populations and denominators. The safety fields list at-risk counts that do not account for all participants reported as randomized. The reason is not reported in the registry record. Reporting who contributed to each outcome and how incomplete data were handled helps readers judge the scope of a result.
Finally, planning calculations should be separated from trial findings. A hypothetical sample-size illustration under specified assumptions is not observed power and cannot repair missing endpoint results. The statistical significance of this case lies in what the record makes possible to conclude: the intended question and the reasons the evidence is limited are visible, while a comparative efficacy estimate is not reported.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main trial-specific limitation is that the registry reports termination due to lack of enrollment and 7 randomized participants, but no primary-outcome analysis. The intended enrollment was 70. No viral-load estimates, between-group contrast, confidence interval, or p-value are reported in the registry record. The central clinical question therefore cannot be evaluated from the posted outcome information.
The record does not describe the primary analysis model, the schedule of nasal-swab measurements, or how the rate of decline was defined. It also does not report endpoint-specific participant counts, analysis populations, missing-data procedures, or a multiplicity plan. These details are needed to understand how a primary estimate would have been produced and how robust it would be to incomplete observations or analytic choices.
The safety fields list at-risk counts of 1 for the active group and 5 for placebo, which do not account for all participants reported as randomized. The reason for the difference is not reported in the registry record. The safety counts therefore have limited interpretability as a complete accounting of randomized participants.
The registry does not report further operational details about the reason for termination, changes to study conduct, or the implementation of masking. These omissions should not be filled by assumptions. The posted record supports a description of the intended design and the available safety counts, but not a reconstruction of trial conduct or a comparative assessment of the primary endpoint.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 — NCT04605588.
- Registry record last updated 2022-05-05; status last verified 2022-05.
- Results first posted 2022-05-05.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
TriACT was a randomized, quadruple-masked, parallel-group phase 2 trial comparing five-day dosing with nitazoxanide, ribavirin and hydroxychloroquine sulfate against five-day placebo. The primary outcome was the rate of viral-load decline over the 10 days after randomization, measured by nasal-swab qPCR. Participants were to be followed for 28 days.
The registry lists the study as terminated due to lack of enrollment. It reports an intended enrollment of 70 and 7 randomized participants. The primary-outcome analysis and treatment-effect estimate are not reported in the registry record. Safety fields list zero serious adverse events and zero deaths in each group, but the at-risk counts do not account for all randomized participants; the reason is not reported in the registry record.